Introduction
In psychiatry, finding the predictors of antidepressant response is important in clinical practice. Given that the serotonin transporter can play a role in the functional modulation of serotonin, many researchers ask if poly-morphisms of the serotonin transporter (5-HTT) gene could predict the treatment response to selective serotonin reuptake inhibitors (SSRI). To date, a number of studies about the relationship between several genetic variants in 5-HTT and treatment response to SSRI have been reported, but it is still controversial. Among those genetic variants of 5-HTT, the serotonin transporter linked promoter region (5-HTTLPR) polymorphism and 5-HTT intron 2 variable number tandem repeat (5-HTTVNTR) are most widely studied.
Some researchers insist that the l/l genotype or l-allele of the 5-HTTLPR gene is associated with treatment response to SSRI [1] [2] [3] . Corroboration by other researchers and meta-analysis also support these findings [4] . However, there also exist negative findings [5] . Moreover, in Asian studies, the direction of the effect of the 5-HTTLPR polymorphism on treatment response to SSRI indicated contradictory results. Several studies [6] [7] [8] have shown that contrary to Caucasian populations, the s/s genotype or s-allele of 5-HTTLPR is associated with a better treatment response to SSRI. However, others [9] have shown that the l/l genotype is associated with a better treatment response.
There are several reports regarding the association between 5-HTTLPR and SSRI side effects. Carriers of the s-allele treated with paroxetine exhibit reduced tolerability and higher discontinuation rates compared to l/l homozygotes [10] , and the s-variant was associated with side effects induced by SSRI [11] . Furthermore, the s-allele was shown to identify patients at risk for developing insomnia and agitation with fluoxetine treatment [12] . Other studies reported no association between 5-HTTLPR and adverse effects induced by SSRI [13, 14] .
5-HTTVNTR has been addressed less than 5-HTTL-PR. Min et al. [15] reported that depressive patients with the 12/12 repeats of 5-HTTVNTR or the l/l genotype of 5-HTTLPR experienced a better clinical response to SSRI or serotonin norepinephrine reuptake inhibitors (SNRI). One Korean study also showed that major depressive disorder (MDD) patients that were homozygous for 12/12 repeats of 5-HTTVNTR or the s/s of 5-HTTLPR showed better responses than all others [7] .
However, only a limited number of pharmacokinetic genetic studies reported the relationship between SNRI, which are frequently used in clinical practice, and serotonin transporter polymorphisms. No influence of 5-HTTLPR polymorphisms on the antidepressant response to milnacipran was detected. In contrast, the presence of the T allele of the NET T-182C polymorphism was associated with a superior milnacipran response [16] . Recently, two Japanese studies showed that the C allele of -1297 C ] G ␣ 2 -adrenergic receptor and the Met/Met genotype of COMT Val158Met polymorphisms are associated with better or faster response to milnacipran [17, 18] . And although the study sample did not consist of depressive patients, the response in venlafaxine-treated obsessivecompulsive disorder patients has been reported to be associated with the l/s genotype of 5-HTTLPR [19] . Therefore, we investigated whether an association exists between venlafaxine and serotonin transporter gene polymorphisms in patients with MDD.
Methods

Subjects
A total of 101 patients with MDD were recruited from 3 general hospitals over a period of 24 months from July 2006 to December 2008. All the patients were Korean, met the DSM-IV criteria for MDD and were diagnosed by the Structural Clinical Interview for DSM-IV. Patients with other axis I disorders (including dementia, substance abuse, panic disorder, obsessivecompulsive disorder and generalized anxiety disorder) and those with axis II disorders, determined by a clinical interview, were excluded. Patients with a history of seizure, brain trauma, cardiovascular disorders or significant physical or neurological disorders were also excluded. The ages of the patients ranged from 20 to 69 years and all had been free of psychotropic drugs for at least 14 days prior to their entry into the study. All study procedures complied with the institutional review board regulations and were conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. After a complete description of the study to the subjects, written informed consent was obtained.
During the treatment period, venlafaxine was administered to all patients daily (in the morning after breakfast at the same dose) for 4 weeks. The initial total dose was 75 mg/day, which after 1 week was increased to 150 mg/day. Additionally, administration of lorazepam (0.5 mg) at bedtime was permitted once per week to patients with insomnia. No other psychotropic drugs were permitted during the study. All types of psychotherapies other than brief supportive psychotherapy were not permitted as well.
Genotyping
Peripheral blood was collected and genomic DNA extracted using standard procedures [20] . The region containing the 5-HTTLPR polymorphism was amplified by PCR using the forward primer 5 -GGCGGTGCCGCTCTGAATGC-3 and the reverse primer 5 -GAGGGACTGAGCTGGACAACAAC-3 , according to a previously described protocol [21] . The long (528 bp) and short (484 bp) PCR-amplified 5-HTTLPR alleles were separated by electrophoresis on 3% agarose gels supplemented with ethidium bromide and visualized by silver staining.
Genotyping of 5-HTTVNTR was carried out according to the method previously described [22] . The primers 8,224 (5 -GTC-AGTATCACAGGCTGCGAG) and 8,223 (5 -TGTTCC TAG TC-TTACGCCAGTG) were used. These primer pairs amplify across the VNTR region of intron 2 that contains the 17-bp repetitive element. PCR was performed in a final volume of 25 l containing 50 ng of genomic DNA, 0.2 m M dNTPs, 10 pmol of each primer, 10 m M Tris-HCl (pH 8.3), 50 m M KCl, 1.5 m M MgCl 2 , 0.01% gelatine and 1 U of Taq DNA polymerase. The PCR amplification consisted of 35 cycles at 95 ° C (1 min), 58 ° C (1 min) and 72 ° C (1 min). Amplified fragments were resolved on 3% agarose gels, and bands were visualized by ethidium bromide staining and ultraviolet transillumination. The genotyping success rates for both 5-HTTLPR and 5-HTTVNTR were 100%.
Assessments
The Hamilton Anxiety Rating Scale (HAM-A) [23] , Beck Anxiety Inventory (BAI) [24] , Hamilton Depression Rating Scale (HAM-D) [25] , Montgomery-Åsberg Depression Rating Scale (MADRS) [26] and Beck Depression Inventory (BDI) [27] were used to evaluate patients at baseline, and after 1 and 4 weeks of treatment. The interrater reliability was 0.80-0.84 for the HAM-A and HAM-D.
Responders were defined by a reduction from baseline in the depressive or anxiety symptom scale score of at least 50%, and remitters were defined by a HAM-D total score of 7 points or less after 4 weeks of treatment. We measured the side effects of venlafaxine treatment using the Toronto Side Effect Scale [28] . For each side effect, we classified the patients into a side effect group and a non-side-effect group. If the patients experienced any kinds of side effects at any time during the 4 treatment periods, we included them into the side effect group. Because of the limited statistical power, we compared the genotype and allelic differences between the 2 groups only in the side effects that occurred in more than 15% of the participants who completed this study.
Drug compliance was judged using a self-report checklist drawn up by each patient regarding their daily schedule and side effects of the medication. Capsule counting was also done during the study. According to the checklist and capsule counting, we excluded 4 patients that showed noncompliance more than twice a week.
Data Analysis
The Hardy-Weinberg equilibrium for genotype frequencies in MDD patients was calculated using 2 tests. Of the remaining 84 patients, a small number of missing values on both the depressive and anxiety scales existed. Because of this small number, the values were not modified by intent to treat, such as the last-observation-carried-forward method. To consider the number of missing values from each scale, we tabulated the number of subjects who were used in the statistical analysis of each scale. Additionally, to confirm our data, we also used repeated measures ANO-VA to find out the relationship between 0-, 1-and 4-week changes of each measurement over time and across genotypes. These factors were a main effect of time (which indicated whether changes in an outcome variable occurred as a function of time, irrespective of genotypes) and a time ! treatment interaction (which indicated whether changes in subjects over time differed between genotypes). Categorical data were analyzed using the 2 test. Odds ratios (OR) with a 95% CI were calculated to estimate the effects of high-risk genotypes and alleles. Logistic regression analysis was used to determine the predictors of venlafaxine treatment response or remission. The cutoff probability value was set at 0.05. SPSS (PC version 13) and was used for statistical analysis. This study had the power (0.8) to detect a medium effect size (w = 0.33) between 2 genotypes (s/s vs. non-s/s) of 5-HTTLPR ( ␣ = 0.05).
Results
Sociodemographic Characteristics
The sociodemographic characteristics of the MDD patients are listed as below: male/female ratio of 40 (40%)/61 (60%), and age of 44.6 8 17.0 years. Each genotype distribution of the 5-HTTLPR and 5-HTTVNTR polymorphism genotypes was in Hardy-Weinberg equilibrium (all p 1 0.05).
A total of 101 subjects with MDD had been recruited. Twenty-three patients (22%) were comorbid with dysthymic disorders. Twenty-nine patients (29%) had disorders of the melancholic type, and 5 patients (5%) had atypical types. Of the 101 patients enrolled, 17 did not complete the study: 8 patients because of side effects, 1 patient because of inefficacy, 4 patients because of partial compliance as determined by a compliance checklist and 4 patients without explanation. Eighty-four MDD patients remained in this study. The baseline scores for age, sex and initial HAM-D between patients who dropped out and those remaining in this study at 4 weeks were not significantly different.
Venlafaxine Short-Term Treatment Response and Genotype Distribution of 5-HTTLPR Polymorphism
There were significant differences in the 5-HTTLPR genotype distribution between responders and nonresponders divided by HAM-D ( 2 = 7.5; p = 0.006), MADRS ( 2 = 11.7; p = 0.0006) and BDI ( 2 = 6.0; p = 0.01) at 4 weeks. That is, the non-s/s genotype showed a significant association with responders for each of the 4-week scale scores ( table 1 ) . There was also a significant difference in the 5-HTTLPR genotype distribution between responders and nonresponders divided by HAM-A at 4 weeks ( 2 = 7.5; p = 0.006). However, no significant difference existed between responders and nonresponders by BAI ( table 3 ) . However, there is no association between 5-HTTVNTR and short-term treatment response The total number of subjects who experienced any kind of side effect during the 4-week treatment period was 60 (71.43%). The side effects reported in more than 15% of the subjects were as follows: gastrointestinal (n = 29; 34.52%); sexual (n = 18; 21.43%); nose, mouth and throat (n = 17; 20.24%); neurological (n = 15; 17.86%) and sleep related (n = 13; 15.48%). There were no significant associations between 5-HTTLPR or 5-HTTVNTR and those side effects (all p 1 0.05; data not presented). Table 5 summarizes the results of the logistic regression analysis, illustrating the possibility of using the 5-HTTLPR genotype as a predictor of venlafaxine treatment response. Multivariate logistic regression analyses (15) ( table 6 ) .
Prediction of Venlafaxine Treatment Response at 4 Weeks Using Logistic Regression Analysis
Discussion
The purpose of this study was to determine the relationship between the 5-HTT polymorphisms and venlafaxine treatment response. Since the 5-HTT polymorphisms, especially 5-HTTLPR, have been suggested to be predictors of SSRI treatment response, and given that venlafaxine is a potent inhibitor of serotonergic reuptake, 2 (5) 16 (22) 18 (27) 40 (73) Val ues in parentheses denote percentages. Table 6 . Prediction of venlafaxine treatment response using logistic regression analysis a hypothesis that venlafaxine treatment response could be related to a 5-HTT polymorphism has been put forth.
Our results indicate that the non-s/s genotype (l/l + l/s) of the 5-HTTLPR polymorphism might be associated with better short-term treatment response to venlafaxine. These results are supported by previous reports that the non-s/s genotype is associated with good treatment response [4] . The mechanism behind these results can be assumed according to the following findings. First, the capability of the l-allele lymphoblast with respect to serotonin transport is twice as high as that of the s-allele lymphoblast [29] , and transcriptional activity, which is regulated by protein kinase A or C, is better in l-allele plasma platelets [30] . Secondly, transport efficacy (V max /K m ), which is the maximum velocity of serotonin transport per substrate utilization, is lower in subjects with the sallele [29] . Thirdly, proinflammatory cytokines, which promote the expression of the serotonin transporter, can be activated in the presence of the l-allele [31] . In contrast, some researchers have reported that the s/s genotype or s-allele is associated with good treatment response to SSRI, especially in Asian populations [7, 8] . Others could not find any significant association between 5-HTTLPR and treatment response to SSRI [5] . The discrepancy between those findings and our results may stem from the following. First, since the mechanisms of action of the SNRI, the treatment response to venlafaxine can be different from the response to SSRI, as in the milnacipran report [16] . Second, differences in ethnicity, symptom severity, duration of treatment, and time points of assessment between this study and previous studies could also be a source of inconsistent results. Recently, Mrazek et al. [3] found that the l/l genotype had a greater likelihood of remission after citalopram treatment in only white non-Hispanic subjects but not in white Hispanic or black subjects. Similar to our study, some other Asian studies showed the association between the non-s/s or l allele of 5-HTTLPR and good response to SSRI [9, 15, 32] . Considering these inconsistent results, further studies using larger sample sizes in various ethnic populations are required in order to verify this relationship.
Although the number of subjects in our study is small, our results suggest that 5-HTTLPR polymorphism can act as a predictor of venlafaxine treatment response. Our study indicated that the side effects of venlafaxine were not associated with 5-HTTLPR or genotype distribution. This result is consistent with previous studies [13, 14] that reported no association between the 5-HTTLPR and side effects of SRIs. However, a recent meta-analysis [33] suggested the strong relationship between 5-HTTLPR and side effects of SSRIs. This discrepancy might come from different ethnicities or the different kinds of anti-depressants (mainly SSRIs vs. venlafaxine) used in studies. In addition, because the sample size in our study is much smaller than that study, our study could not have enough power to detect such an association between 5-HTTLPR and side effects.
In this study, 5-HTTVNTR genotypes showed no significant association with treatment response. This result is partially in line with previous reports [34, 35] . However, a meta-analysis [33] reported that the 12/12 genotype showed a trend toward a better response in Asians. Recently, Mrazek et al. [3] reported that in white nonHispanic subjects, 5-HTTVNTR was associated with remission following treatment with citalopram. However, they also could not find any association between 5-HTTVNTR and remission in white, Hispanic or black subjects. Those findings suggest that the genetic effects of 5-HTTVNTR on the response or adverse reaction to antidepressants can be different according to study populations. However, some Korean studies also reported the association between the l/l genotype of 5-HTTVNTR and better response to SSRI [7] although they did not use venlafaxine. Therefore, further investigations of large samples in various populations are needed.
This study has several limitations. First, due to the limited number of subjects in the study population, the present study can only be regarded as a pilot study and it should be replicated in a larger sample. Considering the small number of subjects who were remitted on the 4th week or who experienced side effects, we could not find any association between the two genes and remission or side effects due to the insufficient statistical power of this study. Second, this study only evaluated short-term treatment responses in MDD patients after 4 weeks of drug administration. However, since a systemic analysis suggested that early treatment response can extend to longterm treatment response, some researchers have insisted that 4 weeks is enough to establish treatment response [36] . Third, we analyzed only two single-nucleotide polymorphisms (SNPs) of 5-HTTLPR and 5-HTTVNTR. However, other variants such as a functional SNP rs25531 have been reported to be associated with treatment response [37] . Therefore, further large-scale studies using tag SNPs which cover the entire gene region as well as the other variations that are supposed to have functional implications are needed. Fourth, we evaluated a relatively low dose (fixed dose of 150 mg) for venlafaxine treatment response; however, it is known that the serotonergic activity of venlafaxine is potent at a relatively low dose [38, 39] , and so we thought that 150 mg would be sufficient to evaluate the relationship between the serotonergic gene, 5-HTTLPR, and treatment response. Fifth, the association of 5-HTTLPR with venlafaxine response should be examined in a placebo-controlled study. We cannot rule out the presence of a population-based stratification bias in the present study. Finally, plasma levels of venlafaxine were not analyzed in these patients. Thus, we do not know exactly the conditions of the drug metabolism. Although we excluded poor drug compliance by a self-report checklist, there might potentially be additional noncompliant patients in this study.
In conclusion, this study has demonstrated that the non-s/s (l/s + l/l) 5-HTTLPR genotype is associated with, and can act as a predictor of, better treatment response to venlafaxine. However, these findings require confirmation via well-designed studies utilizing larger samples before 5-HTTLRP genotyping is considered in the routine clinical evaluation of MDD patients using venlafaxine.
